ARTICLE | Clinical News
Edifoligide E2F decoy: Phase III ongoing
June 28, 2004 7:00 AM UTC
CGTK said that in a final review, a DSMB recommended continuing the company's double-blind, placebo-controlled Phase III PREVENT IV trial in 2,400 patients. ...